Novel therapeutics for immune thrombocytopenia: an evolving treatment landscape

Introduction Immune thrombocytopenia (ITP) is anautoimmune bleeding disorder; its management is shifting from empiricimmunosuppression and splenectomy to targeted, pathway-specific drugs thatraise platelet counts with fewer long-term toxicities.